Find an expert

Dr Abu Sina is currently an NHMRC Emerging Leader Fellow at the Center for Personalized Nanomedicine, Australian Institute for Bioengineering & Nanotechnology (AIBN), The University of Queensland, Australia. Prior to this, he served as a Visiting Scientist at the Dana-Farber Cancer Institute, Harvard University, and as a Visiting Research Fellow at the Irving Cancer Research Center, Columbia University, NY, USA.

Dr. Sina has earned both national and international acclaim for his notable contributions to advancing translational-focused nano-diagnostic technologies with a focus on early cancer detection from liquid biopsies. He is one of the few leaders in the world who is driving the liquid biopsy-based multi-cancer early detection (MCED) test program. He has had several media appearances so far which include interviews on national (Channel 9, Channel 7, ABC News, Fox News, etc.) and international Television (CBC News, CTV News Canada, etc.) and Radio (4EB, 4BC, ABC Perth, ABC Sunshine coast, SBS) outlets.

Actively participating in scholarly discussions, Dr. Sina has served as a Keynote Speaker, Invited Speaker, and Session Chair at various national and international conferences and seminars. His commitment to excellence has resulted in several prestigious awards, including the Metrohm-EDRACI Young Electrochemist Award 2021, the Queensland Health and Medical Research Award 2019 from the Queensland State Government of Australia, and recognition as a Fellow of the International Association of Advanced Materials.

Central to his aspirations is a vision to develop point-of-care diagnostic technologies with the potential to revolutionize early disease detection, thereby enhancing overall quality of life.

Mariusz Skwarczynski completed his Ph.D. in Chemistry in 1999 at Wroclaw University of Technology (Poland). His postdoctoral training began at Tokushima Bunri University (Japan) under the direction of late Professor M. Nishizawa, where he studied the biomimetic total synthesis of anticancer agent paclitaxel. He then joined the laboratory of Professor Yoshiaki Kiso at Kyoto Pharmaceutical University (Japan) to study prodrugs of paclitaxel. In 2004 he was awarded with Japanese fellowship (Japan Society for the Promotion of Science postdoctoral fellowship) and research grant to conduct further research on paclitaxel. He developed novel classes of paclitaxel prodrugs: isotaxoids and phototaxels. He also co-developed an epimerization-free method for the synthesis of novel building blocks (isodipeptides) for solid phase peptide synthesis and these units have been commercialized by Merck-Novabiochem.

In 2008 he joined Professor Istvan Toth group at University of Queensland (Australia) to work on vaccine delivery strategies. Since then, he research is mainly focused on nanotechnology-based peptide vaccine delivery approaches. In 2010 he was awarded with University of Queensland Strategic Fund Research Fellowship. In Australia, he is involved in a wide range of collaborative research projects, both nationally and internationally, to develop vaccines against GAS, HIV, hookworm infections, malaria and cancer, along with antibiotics against multidrug resistant bacteria.

Dr. Alex Smith is a Research Fellow at UQ's School of Chemical Engineering. His interests are in understanding structure: function relationships between complex carbohydrates (such as heparan sulphate) and proteins, and how these interactions can inform the development of glycotherapeutic agents to treat a wide variety of injuries and diseases.

Update Profile

Emeritus Professor Maree Smith AC FTSE FAHMS is a full-time researcher and Director, CIPDD, School of Biomedical Sciences, Faculty of Medicine, The University of Queensland.

In the 12 years prior to her current appointment, Professor Smith led a high-performing team in building the CIPDD and its commercial interface TetraQ, recognized as a unique, GLP-accredited drug development Centre in Australia. Professor Smith has considerable expertise in biomedical discovery/translation with specialist expertise in the novel pain therapeutics discovery/translation field encompassing a portfolio of 16 rodent pain models that mimic individual human pain conditions. This portfolio of models conducted in a purpose-built facility operated in accordance with the requirements of our Quality Management System, making the CIPDD unique in Australia and rare internationally.

In the 15 years prior to establishing the CIPDD, Professor Maree Smith was a full-time academic in the School of Pharmacy. In brief, she joined the School of Pharmacy as a Lecturer in 1989 and was successively promoted through the academic ranks to Professor in 2004. Prior to that she undertook a PhD and early postdoctoral training in clinical pharmacology with specialist expertise in bioanalytical method development, bioanalysis of human plasma samples, drug metabolism and clinical pharmacokinetics. Her second postdoc was in the field of pain management and pain pharmacology.

In the years, 1990-2005, Maree Smith taught in the Drug Discovery stream of the 2nd, 3rd & 4th years of the undergraduate Pharmacy program and she was instrumental in developing innovative courses for the final year of the undergraduate Pharmacy curriculum. She was also instrumental in the development of a course for the M Biotech program at UQ entitled “Quality Systems in Biotechnology” which continues to this day and is a compulsory course in the Program. Maree has successfully advised/co-advised to completion 33 PhD students, 2 Research Masters students and ~50 Honours students. She also served for 14 years as an external evaluator for the TGA.

Maree's Current Research Interests are as follows:

1. Subtle differences in the pathobiology of individual chronic pain conditions

2. Improving preclinical to clinical translation in novel analgesics development

3. Preclinical drug development of novel pain therapeutics

4. Preclinical drug development

Awards

2021 UQ Fellowship

2019 Companion of the Order of Australia (AC) in the Queen's Birthday Honours List

2018 Honorary Bragg Membership (The Royal Institution of Australia)

2016 Bowl of Hygeia Award (Pharmaceutical Society of Australia)

2016 Clunies Ross Knowledge Commercialisation Award (ATSE)

2015 Honoured to be included in inaugural list of Australia's top Innovators; viz Knowledge Nation 100

2015 Inaugural Inductee into the Life Sciences Queensland (LSQ) Hall of Fame

2015 Johnson and Johnson Innovaton AusBiotech Industry Excellen Award - Outstanding Leader category.

2015 Elected Fellow, Australian Academy of Health and Medical Sciences (AAHMS)

2015 Australian Pain Society Distinguished Member Award - For services to the promotion, treatment and science of pain management and lifelong contribution to the Australian Pain Society

2013 UQ Top 5 Inventor - Award by Thomson Reuters and UQ at inaugural Awards

2013 UQ Top 5 Innovator - Award by UniQuest Pty Ltd and UQ at inaugural Awards

2012 Queensland Life Sciences Industry Excellence Award jointly with Dr Jim Aylward

2011 Elected Fellow, Australian Academy of Technological Sciences (ATSE)

2009 Honorary Fellowship, Faculty of Pain Medicine, ANZCA (Australian and New Zealand College of Anaesthetists).

2008 WiT (Women in Technology): Biotech Outstanding Achievement Award

2002 Meritorious Mention for Sustained Excellence in Research Higher Degree Supervision

2001 Meritorious Mention for Sustained Excellence in Research Higher Degree Supervision

Professor Heather Smyth is a flavour chemist and sensory scientist who has been working with premium food and beverage products for more than twenty years. With a background in wine flavour chemistry, her expertise is in understanding consumer enjoyment of foods and beverages in terms of both sensory properties and composition.

Smyth has a special interest in describing and articulating food quality, understanding regional flavours of locally grown Australian produce, and modelling food flavour and textural properties using instrumental measurements. Smyth also specialises in researching how human physiology and psychology can impact sensory perception and therefore food choice.

I began my scientific career with a Bachelor of Science in Biochemistry and Chemistry, followed by a Bachelor of Science with First Class Honours in Chemistry from Massey University, New Zealand. My honours project focused on developing hydrogels for controlled peptide release in the gut. I then pursued a PhD at Massey University, working on synthetic anti-cancer drugs based on cyclodextrins.

After completing my PhD, I worked as a Research Officer at the New Zealand Veterinary Pathology Epicentre, refining my diagnostic research skills. I continued my career as a Postdoctoral Fellow at Kansas State University, contributing to the detection and surveillance of zoonotic diseases in the swine industry.

Currently, at the University of Queensland, I integrate my expertise in synthetic peptides with vaccine development. My research bridges medical and agricultural biotechnology, focusing on innovative adjuvants and vaccines that span medicinal chemistry, nanotechnology, and immunology, aiming to enhance both health outcomes and agricultural practices.

I am a medicinal and organic chemist

Studied organic chemistry at the University of Sydney, moved to UQ in 1993, then worked for Bayer in Germany, before moving back to Australia in 1996. Worked in Melbourne at the Victorian College of Pharmacy (now MIPS). I then returned to UQ in 2000 to the Fairlie lab where we design and synthesise new chemical entities to tackle human disease. Since 2012 I have been on extended medical leave and am currently an Adjunct Research Fellow, researching proteins from flaviviruses such as Dengue, West Nile, and Zika viruses, and the coronaviruses SARS, MERS, and SARS-CoV-2.

Jason Stokes is a Professor in the School of Chemical Engineering and leads the Premium Food and Beverages Program in Australia’s Food and Beverage Accelerator. This program focuses on industry-driven research to enhance onshore value-adding and business growth opportunities. Jason obtained his BE (Chem) and PhD from University of Melbourne, and was a Researcher with Unilever R&D United Kingdom from 1999-2008, before joining UQ in 2008.

Jason is a recognized expert in the rheology, lubrication, structure and processing of complex fluids and soft materials, including food and beverages. He pioneered the development of rheology and soft contact tribology techniques to provide new insights into oral processing and sensory perception that includes mouthfeel, taste and flavour. His research has uncovered the physical and structural properties driving the complex sensory attributes of a wide variety of food and beverages. These are used by industry to engineer next-generation foods with improved quality and sustainability.

He served in a leadership role as Deputy Associate Dean Research in the Faculty of Engineering, Architecture and IT (EAIT), 2020-23, with a specific focus on research training, development and well-being of emerging researchers. He has previously held other senior roles inlcude Acting Associate Dean of Research in Faculty of EAIT and Director of Research in the School of Chemical Engineering.

Some key areas of his research include:

1. Rheology, tribology, and interfacial properties of soft matter, food and beverages, including development of methods to uncover relevant material properties of food and beverages driving mouthfeel, texture and flavour. .
2. Soft materials and Soft matter such as gels, soft glasses, suspensions, microgels, emulsions and foams, with particular emphasis on using fundamental approaches to uncover structure-property relationships for complex systems.
3. Colloids and hydrocolloids such as nanocrystalline cellulose, microgels, polysaccharides, proteins and starches.
4. Development of structure-property-processing relationships for rational design of food and beverages, including dairy & plant-based and solids & liquids.
5. Aqueous lubrication, transport phenomena and flow of non-Newtonian fluids and their application across various industries (minerals, waste, foods, firefighting fluids, polishing fluids).

Professor Stokes lectures and coordinates teaching modules in the Chemical Engineering degree, with particular strengths in Fluid Mechanics and currently coordinates and lectures both Transport Phenomenon (CHEE4009) and Engineering Placement (ENGG7292) courses.

Dr Ekaterina Strounina is a Solid State NMR facility manager in the Centre for Advanced Imaging. She has been working in UQ since 2002, specializing in high-field MRI applications and solid-state NMR spectroscopy.

Critical Care Medicine focuses on supporting patients, often with one or multiple organ failures. Based at the largest Australian cardiac hospital, our research investigates better ways to support patients with heart and/or lung failure. We explore technological, pharmacological and engineering advances that could help our patients to live longer and better. Our group is world-renowned for clinically relevant large animal models, including heart failure, respiratory failure (ARDS), heart transplantation, sepsis, cardiogenic shock, and more. All our studies use hospital-grade equipment and follow the same clinical guideline to maximise translation. We actively take on honours, MPhil and PhD students from multi-disciplinary backgrounds (science, engineering, medicine, allied health), with a successful track record in supporting our students to secure their own grants and funding. Students are expected to contribute to other studies of the group. For more information about the group, please visit ccrg.org.au, and email if you are interested to join us.

Dr Phong Thai is an ARC Mid-Career Industry Fellow. Phong joined Queensland Alliance for Environmental Health Sciences (QAEHS) in 2018 after his Vice Chancellor Senior Research Fellowship at the International Laboratory of Air Quality and Health at Queensland University of Technology. His research focus at QAEHS involves the expansion of wastewater-based epidemiological approach to estimate community consumption and exposure to a range of licit and illicit substances including tobacco and alcohol, pharmaceuticals and as well as the monitoring of community infection to Covid-19 during the last pandemic. He is a member of the team who manage the National Wastewater Drug Monitoring Program.

Phong is also working on projects monitoring occurence, fate and transport of environmental pollutants in different matrices. He has lso far ed or contributed to several exciting projects totalling > A$ 15 millions.

Professor Kevin Thomas is Director of the Queensland Alliance for Environmental Health Sciences (QAEHS). Kevin is an environmental health scientist with a particular interest in understanding the environmental exposures associated with contaminants of emerging concern (CECs) with the goal of protecting environmental and human health. Kevin also leads the Minderoo Centre- Plastics and Human Health at UQ and is Deputy-Director of the Australian Research Council Industrial Transformation Training Centre for Hyphenated Analytical Separation Technologies (HyTech).

His current research is focused on understanding human exposure to plastics pollution and developing mass spectrometric analytical methods for characterizing plastics and other CECs, assessing community-wide health status through analysing wastewater (wastewater-based epidemiology) and establishing alternative approaches to exposure monitoring, for example explanted silicone prostheses and wristbands.

Author of over 300 peer-reviewed papers and Associate Editor for the journal Science of the Total Environment, Kevin is a strong collaborative researcher having founded the international SCORE network on sewer biomarker analysis for community health assessment (see www.score-network.eu) and together with colleagues has recently launched InSpectra- A platform for identifying emerging chemical threats.

Professor Kris Thurecht has appointments at AIBN and UQ’s Centre for Advanced Imaging where he is the Deputy Director of Imaging Technologies. Professor Thurecht has been recognised for scientific excellence with a 2012 Queensland Young Tall Poppy Science Award and a 2010 UQ Foundation Research Excellence Award for his work in developing polymer ‘theranostics’. In 2015 he was recognised by the Royal Australian Chemical Institute Polymer Division through award of the David Sangster Polymer Science and Technology Award for scientific excellence for a mid-career researcher. Since obtaining his PhD in 2005, he has been the recipient of five competitive national and international fellowships, the latest being an NHMRC CDF, and prior to that award an ARC Future Fellowship. He has contributed scientific and review articles to various leading journals in his field, including invited articles in the Emerging Young Investigator issue of Chemical Communications and a Young Talent article in Macromolecular Chemistry and Physics. Professor Thurecht has been chief investigator on grants from various funding bodies, including ARC Discovery grants; ARC Linkage Grants, with both national and international companies; National Health and Medical Research Council (NHMRC) grants; and funding from various cancer foundations. He is co-inventor on 8 patents. He is CI on the ARC Training Centre for Innovation in BioMedical Imaging Technology in which he is theme leader, and is Director of the ARC Research Hub for Advanced Manufacture of Targeted Radiopharmaceuticals.

Professor István Tóth is Chair in Biological Chemistry at The University of Queensland (UQ), Brisbane, Australia, and Affiliated Professorial Research Fellow at the Institute of Molecular Biosciences, UQ. He graduated with a degree in Chemical Engineering from the Technical University, Budapest, Hungary and was awarded his PhD for his Alkaloid Chemistry research. Professor Tóth undertook a postdoctoral fellowship at Carleton University, Ottawa Canada before returning to Hungary to work as a Research Associate, then Scientific Group Leader at the Central Research Institute for Chemistry, Hungarian Academy of Science. He joined the School of Pharmacy at the University of London in 1987 as a Senior Lecturer and Royal Society sponsored Senior Research Fellow. He became a Reader in Medicinal Organic Chemistry in 1994 and was awarded a Doctor of Science degree (DSc 1994) for his work in Drug Delivery (Hungarian Academy of Sciences), before relocating to the University of Queensland in 1998 where he has built a productive research group. Professor Tóth was a visiting professor at the School of Pharmacy, University of London (1994-2004) and at the Department of Bioengineering and Therapeutic Science, University of California, San Francisco (2011-2013). Professor Tóth’s major research interests are: drug delivery, immunoadjuvants, carbohydrates, lipids, peptides, nucleosides, and nucleotides. This research has attracted over $85 million in competitive grants, research contracts and investment funds in the past 10 years. Professor Tóth has over 500 peer-reviewed publications, 45 patents, and an excellent track record in research commercialisation. He is a one of key founders of Alchemia, Implicit Bioscience Pty Ltd, Neurotide Pty Ltd and TetraQ (the commercial arm of Centre of Integrated Preclinical Drug Development). Professor Tóth is an elected RACI Fellow and Fellow of the Queensland Academy of Arts and Sciences. and Feklloiw of the Hungarian Academy of Sciences (since 2016) In 2009 he was awarded the Adrian Albert award for sustained and outstanding research in medicinal biochemistry, and a Business/Higher Education Round Table (BHERT) Award for Outstanding Achievement in International Collaborative Research and Development he obtained the Doctor Honoris Causa degree at Semmelweis university budapest Hungary (2019). Professor Tóth was appointed as a member of the ARC College of Experts (2008-2010). He was the founding (2007) then the elected (2008-2009) President of the Australian Chapter of Controlled Release Society.

Professor Matt Trau is currently a Professor of Chemistry at The University of Queensland (UQ); and is also Senior Group Leader and co-founder of the Australian Institute for Bioengineering and Nanotechnology. Since graduating from the University of Sydney (BSc Hons I, University Medal) and the University of Melbourne (PhD in Physical Chemistry, 1993), he has held positions in industry and academia across the globe. These include a Fulbright Research Fellowship at Princeton University, USA; and a research scientist at Dow Chemical and ICI Pty Ltd. Professor Trau has been a Visiting Professor at two of the largest Cancer Research Centres in the world: The Dana Farber Cancer Research Institute, Harvard Medical School, Boston (2000); and the Fred Hutchinson Cancer Research Centre, Seattle (2008). Professor Trau is internationally recognised for his innovative and cross-disciplinary research at the interface between chemistry, nanotechnology, biology and medicine. He has co-authored more than 290 refereed publications, many of which appear in the highest impact journals in his field, e.g., fifteen Science and Nature family publications. His major awards and honours include an ARC Laureate Fellowship, an ARC Federation Fellowship (amoungst the most prestigious scientific fellowships in Australia), a Fulbright Research Fellowship to the USA; a Queensland Young Tall Poppy Award; a UQ Foundation/Vice Chancellor’s Research Excellence Award; a Paul Harris Fellowship; and a Pink Circle Award for breast cancer research excellence.

Dr Ben Tscharke is an analytical chemist with a keen interest in quantifying analytes in environmental samples. Ben is currently a Senior Research Fellow at the University of Queensland research institute, Queensland Alliance for Environmental Health Sciences (QAEHS), joining in February 2017 after graduating his PhD from the University of South Australia the previous year. His key focus at QAEHS involves the wastewater based epidemiological approach to determine community consumption and exposure to a range of illicit drugs, pharmaceuticals and personal care products. He leads the Australian Criminal Intelligence Commission's National Wastewater Drug Monitoring program at UQ, which collaborates with the University of South Australia (https://www.acic.gov.au/publications/intelligence-products/national-wastewater-drug-monitoring-program-report).

Karnaker's research interests are natural products, peptide-based drug discovery and development, formulation chemistry and non-viral gene delivery system. Karnaker co-inventor and developed a novel, bioresponsive disulphide-linker technology, which has been used for non-viral vectors, peptide-therapeutics for pain and cancer treatment. Karnaker is also keen interest for topical, mucosal drug delivery using a range of dendrimer, nano and microbubbles, lipid and polymer-based nanoparticle systems in conjugation with both biological and physical stimuli-responsiveness.

Karnaker received a PhD in Pharmaceutical Chemistry from The University Queensland under the supervision of Dr Harendra Parekh and Dr Defang Ouyang. Prior to PhD, he completed a Master degree in Pharmaceutical Analysis and Quality assurance (India). Also worked as analytical research and development chemist for one year in a Pharma company. Since 2016, he his working with Dr Parekh team on a range of Industry-funded research projects and his role involves from ideation, research plan, execution, product delivery to industry partners on major platforms such as peptide-based therapeutics, gene therapy and sol-gel technology.

Associate Professor Ryan Turner is the Director of the Reef Catchments Science Partnership at the University of Queensland (a partnership with the Department of the Environment, Tourism, Science and Innovation). Ryan was previously the Department's Principal Scientist for Water Quality and Investigations and held an Adjunct Associate Professor role at Queensland University of Technology in the Managing for Resilient Landscapes, Institute for Future Environments. For 14 years, Ryan managed multimillion-dollar water quality monitoring programs assessing the impacts of sediments, nutrients, and pesticides in numerous catchments along the Queensland coast discharging to the Great Barrier Reef and Moreton Bay. Ryan has been on several steering committees and technical advisory panels, such as the Great Barrier Reef Foundations Technical Advisory Panel. He has published extensively (>80 papers and reports) and led several Queensland Government – Academic collaborative research projects. Ryan previously supervised analytical chemistry and microbiology laboratories in the private and public sectors. Ryan has developed numerous methodologies and standard operating procedures for analytical and monitoring techniques (water quality, sediments and soils). Ryan’s passion for the future of water security is what keeps him striving forward.